Skip to main content
. 2023 Jul 26;94:104728. doi: 10.1016/j.ebiom.2023.104728

Table 1.

Clinical characteristics of AIS/MIA and LUAD among pGGO, mGGO and solid nodule in our study cohort (n = 197).

Clinical variable AIS/MIA
AIS/MIA
AIS/MIA
P LUAD
LUAD
LUAD
P
pGGO (n = 67) mGGO (n = 30) Solid (n = 1) pGGO (n = 3) mGGO (n = 32) Solid (n = 64)
Sex, n (%) 1 0.22
 Female 46 (68.7) 21 (70.0) 1 (100.0) 2 (66.7) 20 (62.5) 30 (46.9)
 Male 21 (31.3) 9 (30.0) 0 (0.0) 1 (33.3) 12 (37.5) 34 (53.1)
Age, n (%) 0.36 0.42
 ≤60 46 (68.7) 17 (56.7) 1 (100.0) 1 (33.3) 15 (46.9) 23 (35.9)
 >60 21 (31.3) 13 (43.3) 0 (0.0) 2 (66.7) 17 (53.1) 41 (64.1)
Smoking, n (%) 0.97 0.14
 Never 51 (76.1) 22 (73.3) 1 (100.0) 2 (66.7) 26 (81.2) 41 (64.1)
 Ever 16 (23.9) 8 (26.7) 0 (0.0) 1 (33.3) 6 (18.8) 23 (35.9)
Histology, n (%) <0.05
 Lepidic / / / 2 (66.7) 9 (28.1) 3 (4.7)
 Acinar / / / 1 (33.3) 17 (53.1) 40 (62.5)
 Papillary / / / 0 (0.0) 6 (18.8) 10 (15.6)
 Solid / / / 0 (0.0) 0 (0.0) 9 (14.1)
 IMA / / / 0 (0.0) 0 (0.0) 2 (3.1)
P stage, n (%) 0.32 0.15
 AIS 19 (28.4) 5 (16.7) 0 (0.0) / / /
 MIA 48 (71.6) 25 (83.3) 1 (100.0) / / /
 IA / / / 3 (100.0) 22 (68.7) 31 (48.4)
 IB / / / 0 (0.0) 7 (21.9) 20 (31.3)
 IIIA / / / 0 (0.0) 3 (9.4) 13 (20.3)
Tumor size, n (%) 0.27 <0.05
 (0,1] 47 21 1 1 4 2
 (1,2] 13 3 0 2 18 21
 (2,3] 2 1 0 0 8 25
 (3,6] 0 0 0 0 2 16
 NA 5 5 0 0 0 0

AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; LUAD, lung adenocarcinoma; GGO, ground-glass opacity; pGGO, pure ground-glass opacity; mGGO, mixed ground-glass opacity; IMA, invasive mucinous adenocarcinoma.